[Market Feature] Inbiozen Surges Over 7% on Rising COVID-19 Cases

On September 1, Inbiozen showed strong performance in early trading. This is due to a recent increase in COVID-19 cases.

As of 9:32 a.m. on this day, Inbiozen was trading at 13,100 won, up 910 won (7.47%) from the previous trading day.

This is interpreted as a result of investors focusing on Inbiozen, which is considered a related theme stock, as concerns over a resurgence have grown due to the recent rise in COVID-19 cases.

Inbiozen is a company that mainly operates a kiosk distribution business and also has a diagnostic kit business. As a result, when the impact of COVID-19 spreads, the company is classified as a related stock due to the increased possibility of contactless transactions.

According to the Korea Disease Control and Prevention Agency, the number of COVID-19 patients hospitalized in 221 sample hospitals nationwide increased from 302 in the 33rd week of this year (August 10-16) to 367 in the 34th week (August 17-23).

The COVID-19 virus detection rate stood at 32.6% in the 34th week, remaining at a similar level after a significant increase at the end of June, with fluctuations over the past three weeks. The concentration of the virus detected in wastewater monitoring has been steadily rising since the 26th week.

The Korea Disease Control and Prevention Agency forecasts that the current trend will continue for the next one to two weeks. The agency plans to monitor the impact of upcoming school openings and other factors.